Issue |
Vis Cancer Med
Volume 6, 2025
|
|
---|---|---|
Article Number | 10 | |
Number of page(s) | 6 | |
DOI | https://doi.org/10.1051/vcm/2025012 | |
Published online | 31 July 2025 |
Review Article
Advances in basic and translational research on the heterogeneity and metastatic mechanisms of primary liver cancer
1
Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, PR China
2
International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University, Beijing, 100191, PR China
3
St Peters Lutheran college Indooroopilly School, 66 Harts Road Indooroopilly, 4068, Brisbane, QLD, Australia
4
Translational Cancer Research Center, Peking University First Hospital, Beijing, 100034, PR China
* Corresponding author: zhangning@bjmu.edu.cn
Received:
24
June
2025
Accepted:
5
July
2025
Primary liver cancer remains one of the most prevalent malignancies worldwide. Despite recent progress in targeted therapies and immunotherapies, clinical benefits are limited to a small subset of patients. Drug resistance, metastasis, and disease recurrence continue to impede therapeutic success. Moreover, the heterogeneity of tumor cells and the immune microenvironment has emerged as a major barrier to effective treatment. This review systematically summarizes advances from our laboratory in elucidating the molecular and cellular heterogeneity of primary liver cancer, encompassing tumor genomic evolution, phenotypic diversity, and immune ecosystem complexity. We further highlight the application of patient-derived organoid models for pharmacogenomic profiling, biomarker discovery, and therapeutic development. Finally, we discuss future directions integrating single-cell multi-omics, organoid-based functional screening, and large-scale clinical cohort studies to advance precision medicine in liver cancer. Collectively, these efforts provide critical insights into the biology of primary liver cancer and inform new strategies to improve patient outcomes.
Key words: Primary liver cancer / Tumor heterogeneity / Tumor immune microenvironment / Drug resistance / Organoids / Single-cell RNA sequencing
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.